Glossary
Amyopathic dermatomyositis
The muscles are fine, and that isn't the good news it sounds like at all. In this form of the illness the lungs take the whole weight instead of the muscles, which is not where anybody looks first. That reversal is the reason this page exists and the reason a team moves quickly.
What the research found.
One study followed 114 people with myositis-related lung disease, of whom 43 had the clinically amyopathic form. All-cause mortality across the group was 27.2 percent. On multivariate analysis, four things independently predicted death, and having this diagnosis rather than polymyositis was one of the four.
One meta-analysis measured what predicts fast-moving lung disease in anti-MDA5 dermatomyositis. Lactate dehydrogenase separated the groups best, at a mean difference of 75.94 whose true value sits from 64.20 to 87.67, at P under 0.00001. Fever predicted it at an odds ratio of 3.16, from 2.12 to 4.72.
One national cohort of 742 people confirmed anti-MDA5 in 24 of them, or 3.23 percent, with lung disease found in 58.3 percent of those. Creatine kinase and C-reactive protein stayed low even in that group. What was raised instead was lactate dehydrogenase, in 91.7 percent of the whole cohort.
Mogyorossy and colleagues, Journal of Clinical Medicine, 2026
One study of 16 people with this diagnosis and lung disease found anti-MDA-5 in 10 of them, or 63 percent. Those 10 had significantly lower survival than the rest. All six deaths in the study were in that group, each from lung disease within 92 days of the first visit despite intensive treatment.
What this illness is
Amyopathic dermatomyositis is dermatomyositis that shows the skin rash without any of the muscle weakness. The rash is there and the weakness isn't, and the word amyopathic is simply the medical way of saying so. Muscle strength and the muscle blood tests come back normal or close to it.
That sounds on the face of it like a milder form of the illness, and it isn't one. The reason it isn't takes a moment to explain, and it's the whole point of this page and of everything below it. Where the risk went when it left the muscles is the question.
Why normal muscles aren't the good news
In the usual form of dermatomyositis, muscle weakness is the main problem and the thing everybody watches. Here that part of the picture is simply absent. Attention has to go somewhere else entirely, and it goes to the lungs, where the evidence says it belongs.
One study followed 114 people with myositis-related lung disease. Of those, 30 had polymyositis, 41 had dermatomyositis, and 43 had the clinically amyopathic form, with all-cause mortality across the whole group at 27.2 percent. On multivariate analysis, four things independently predicted death, which were an acute or subacute course, a lower forced vital capacity on lung testing, age, and having a clinically amyopathic diagnosis rather than polymyositis.
So the absence of muscle disease isn't reassuring in this setting at all. It was one of the four things that predicted a worse outcome. That is the reverse of what almost everybody assumes when they first hear the name of this illness.
Why your muscle tests look normal
Creatine kinase is the blood test that reflects muscle damage, and in this form of the illness it stays low. That's just what you would expect when the muscle isn't the tissue under attack. One national cohort of 742 people found anti-MDA5 in 24 of them, and among that group the median creatine kinase at diagnosis was 193.5 units per liter.
Median C-reactive protein in that group of 24 was 4.24 milligrams per liter, and both measures stayed low even in the people who had lung disease. So a normal creatine kinase tells you something true about your muscles. It tells you nothing at all about your lungs, and those are different questions with only one of them being answered.
The blood test that does move
Lactate dehydrogenase is the one to know about, and two of the studies here point straight at it. In that national cohort of 742 people it was raised in 91.7 percent. Creatine kinase stayed low in those people, and so did C-reactive protein, which is the pairing that makes this test the one to watch.
One meta-analysis went further and asked which measures separate fast-moving lung disease from the slower kind in anti-MDA5 dermatomyositis. Lactate dehydrogenase came out strongest, at a mean difference of 75.94, whose true value sits from 64.20 to 87.67, at P under 0.00001. Read that interval, because it runs from 64.20 to 87.67 and never comes near zero.
That's an unusually clean separation for a blood test to manage. Two other tissue markers came out weaker than it. Aspartate aminotransferase came in at a mean difference of 24.35, from 8.74 to 39.96, and alanine aminotransferase came in at 26.20, from 10.04 to 42.36.
The antibody that splits this in two
Anti-MDA5 is the single biggest fork in this illness, and it's worth knowing which side of it you're on. One study looked at 16 people with this diagnosis and lung disease, and anti-MDA-5 was found in 10 of them, or 63 percent. Those 10 had significantly lower survival than the rest.
All six deaths in the study were in that group. Each died of lung disease that hadn't responded to treatment, within 92 days of their first visit, despite intensive treatment. Read that for what it is, which is sixteen people studied and six of them dying, rather than a timeline anybody is on.
That study also found a difference in what the scans showed between the two groups, which is worth a line. A hazy subpleural shadowing with irregular lines predominated in the antibody-positive people. Consolidation running alongside the airways and blood vessels predominated in the negative ones.
How common that antibody is
It's uncommon, which is worth putting beside the survival figures above. One national cohort across four centers confirmed anti-MDA5 in 24 of 742 people, which works out at 3.23 percent of the whole group. Median age at diagnosis was 49.5 years, with a range running all the way from 24 to 81.
Within that group of 24, the classic form of dermatomyositis was still the commonest at 75 percent. The clinically amyopathic form and polymyositis each accounted for 12.5 percent, while lung disease was identified in 58.3 percent of them. So most people with dermatomyositis don't have this antibody at all.
Knowing whether you do beats assuming it either way, and it's a fair thing to ask about at your next appointment. What the answer changes is how closely your lungs get watched from here on. It doesn't change who you are or anything you were told last week.
What else predicts fast-moving lung disease
That meta-analysis looked beyond the blood tests as well, and two other things predicted it. Both of them are things a person can notice for themselves. Fever predicted it at an odds ratio of 3.16, whose true value sits from 2.12 to 4.72, at P under 0.00001.
Anti-Ro-52 positivity predicted it at 2.87, from 1.52 to 5.40, at P equals 0.001. A separate national cohort found anti-Ro52 in 45.8 percent of people overall, and among those who had lung disease it reached 71.4 percent. It predicted lung disease there at an odds ratio of 22.5, at P equals 0.0045.
That last interval runs from 2.10 to 240.48, which is a hundredfold range drawn from 24 patients. What it means is that the direction is real while the size of the effect is anybody's guess. Read the direction and leave the number where it sits.
What to report
The list here is short and most of it covers breathing, though one item on it doesn't. New breathlessness counts, and so does breathlessness that has got worse. A cough that won't settle counts as well, and so does getting out of breath on stairs when you didn't before.
Fever belongs on the list too, because it's one of the things that predicted fast-moving lung disease in the meta-analysis above. So does anything that feels like a chest infection coming on, or a fever with no obvious cause behind it. None of those on its own means something bad is happening to you.
All of them are worth reporting rather than watching, which is a different standard from most of what this site says. The reason for that is everything above rather than any one figure in it. On this page in particular, the people looking after you would rather hear early.
Common misconceptions.
Myth. No muscle weakness means a milder illness.
Reality. It's the opposite of milder here, and one study shows why. It followed 114 people with myositis-related lung disease, where having this diagnosis rather than polymyositis predicted death on its own. The muscle is spared and the lungs aren't, so in this group the lungs are what the outlook turns on.
Myth. Normal muscle blood tests mean things are stable.
Reality. Not in this form of the illness, and one national cohort watched the numbers to show it. Creatine kinase stayed low even in people who had lung disease, at a median of 193.5 units per liter, and C-reactive protein stayed low as well. What was raised instead was lactate dehydrogenase, in 91.7 percent of the group, so the usual muscle markers are the wrong place to look.
Myth. Fast-moving lung disease comes out of nowhere.
Reality. Several things predict it, and one meta-analysis ranked them. Lactate dehydrogenase separated the groups best, at a mean difference of 75.94 from 64.20 to 87.67, while fever predicted it at an odds ratio of 3.16 from 2.12 to 4.72. Anti-Ro-52 predicted it at 2.87, from 1.52 to 5.40, and none of that is a guarantee in either direction.
Myth. The antibody is just a label.
Reality. It's the single biggest fork in this illness rather than a line in a file. One study of 16 people found anti-MDA-5 in 10, and all six deaths in that study were in that group. A national cohort looked at a second antibody, finding anti-Ro52 in 71.4 percent of those with lung disease and predicting lung disease at an odds ratio of 22.5, on an interval running from 2.10 to 240.48.
Myth. This is a common form of dermatomyositis.
Reality. It isn't common, and neither is the dangerous antibody. One national cohort of 742 people confirmed anti-MDA5 in 24, which works out at 3.23 percent. Within that small group classic dermatomyositis was still commonest at 75 percent, with the clinically amyopathic form at 12.5 percent, so this page describes an uncommon corner of an uncommon illness.
Related terms.
- Myositis, the wider group of muscle inflammation illnesses.
- Antisynthetase syndrome, the other myositis subtype where lungs dominate.
- Myositis blood tests, for what the blood results mean.
Questions patients ask.
What is amyopathic dermatomyositis?
Dermatomyositis that shows the skin rash without the muscle weakness, which is what the word amyopathic is describing. The rash looks much as it does in the usual form, while muscle strength and the muscle blood tests come back normal or close to it. That combination is the whole of what the name means.
Is it milder without the muscle part?
It's the opposite of milder here, and one study shows why. It followed 114 people with myositis-related lung disease, where having this diagnosis rather than polymyositis predicted death on its own. The muscle is spared and the lungs aren't, so in this group the lungs are what the outlook turns on.
Why do my muscle tests look normal?
Because the muscle isn't the tissue under attack in this form of the illness. One national cohort watched creatine kinase, which is the blood test that reflects muscle damage, and it stayed low even in people who had lung disease, at a median of 193.5 units per liter. A normal one says something true about your muscles and nothing at all about your lungs.
Which blood test does move?
Lactate dehydrogenase, on two of the studies gathered here. One national cohort found it raised in 91.7 percent of the group, and one meta-analysis ranked it first for separating fast-moving lung disease from the slower kind. The mean difference was 75.94, from 64.20 to 87.67, at a P value under 0.00001.
What is anti-MDA5?
An antibody that marks out the most dangerous form of this illness. One study covered 16 people with this diagnosis and lung disease and found the antibody in 10 of them, who had much lower survival. All six deaths in that study were in that group, each within 92 days of a first visit.
How common is that antibody?
It's uncommon, which is worth setting beside everything above. One national cohort of 742 people confirmed it in 24, or 3.23 percent, and lung disease was found in 58.3 percent of those 24. So most people with dermatomyositis don't have it, and it's worth knowing whether you do rather than assuming either way.
What predicts fast-moving lung disease?
One meta-analysis looked directly at that question and ranked the answers. Lactate dehydrogenase separated the groups best, at a mean difference of 75.94 from 64.20 to 87.67, while aspartate aminotransferase came next at 24.35, from 8.74 to 39.96. Fever predicted it at an odds ratio of 3.16, and anti-Ro-52 at 2.87.
What should I report?
Anything new about your breathing, and quickly rather than at your next appointment. Breathlessness that's new or worse counts, a cough that won't settle counts, and so does getting out of breath on stairs when you didn't before. Fever belongs on the list too, because it's one of the things that predicted fast-moving lung disease.
References.
- Fujisawa T; Hozumi H; Kono M et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824. 10.1371/journal.pone.0098824Retrospective analysis of 114 consecutive patients diagnosed with interstitial lung disease associated with polymyositis
- Liu T; Ji X; Wei Y et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis. Rheumatology (Oxford, England). 2026;65. 10.1093/rheumatology/keag311Systematic review and meta-analysis of 27 cohorts
- Mogyoróssy S; Griger Z; Tarr T et al. Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort. Biomedicines. 2026;14. 10.3390/biomedicines14030709Retrospective multicentre study of anti-MDA5 positive Caucasian patients managed at four Hungarian rheumatology centres between 2020 and 2025
- Ikeda S; Arita M; Morita M et al. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?. BMC Pulm Med. 2015;15:159. 10.1186/s12890-015-0154-4Retrospective review of medical records of patients diagnosed with clinically amyopathic dermatomyositis and interstitial lung disease at one hospital from January 2005 to September 2014
- Fujisawa T; Hozumi H; Kono M et al. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. Respir Investig. 2017;55:130-137. 10.1016/j.resinv.2016.09.006Retrospective analysis of 34 patients with interstitial lung disease associated with polymyositis
- Liang J; Xu D; Sun C et al. Hemophagocytic Lymphohistiocytosis: Prevalence, Risk Factors, Outcome, and Outcome-related Factors in Adult Idiopathic Inflammatory Myopathies. J Rheumatol. 2020;47:1532-1540. 10.3899/jrheum.190542Retrospective case-control study of patients with dermatomyositis
- Correia BP; Campanilho-Marques R; Dourado E et al. Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center. J Clin Med. 2024;13. 10.3390/jcm13206085Retrospective study of 198 patients with idiopathic inflammatory myopathy followed at a Portuguese tertiary centre between June 2016 and March 2024
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.